Imatinib Mesylate ( DrugBank: Imatinib )


5 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
28Systemic amyloidosis1
34Neurofibromatosis4
51Scleroderma7
86Pulmonary arterial hypertension16

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

28. Systemic amyloidosis


Clinical trials : 267Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

34. Neurofibromatosis


Clinical trials : 133Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

86. Pulmonary arterial hypertension


Clinical trials : 1,205Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries